(BUSINESS WIRE)– NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Natpara® (parathyroid hormone) as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Hypoparathyroidism is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone, or PTH. Natpara, a bioengineered replica of human PTH, is expected to be available in the second quarter of 2015… Read more »
Shares of NPS Pharmaceuticals closed yesterday at $45.64 . NPSP has a 1-year high of $45.75 and a 1-year low of $22.11. The stock’s 50-day moving average is $38.38 and it’s 200-day moving average is $30.74.
On the ratings front, NPS Pharmaceuticals has been the subject of a number of recent research reports. In a report published on January 13, analyst Rohit Vanjani from Oppenheimer assigned a Buy rating to NPSP, with a price target of $1, which represents a potential downside of 97.8% from where the stock is currently trading. Separately, on the same day, Barclays’ Geoff Meacham downgraded NPS Pharmaceuticals shares to Hold and has a price target of $46.
In total, one research analyst has assigned a Hold rating and 4 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $45.64 which is -13.7% under where the stock closed yesterday.
NPS Pharmaceuticals Inc is involved in the development of new treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs.